Back

Characteristics of patients initiating PCSK9i mAb following myocardial infarction and comparability of treatment groups in the Netherlands

28 August 2023 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: PCSK9 inhibitors and inclisiran Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Queenie Chan

Amgen Ltd, Greater London (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)
Doctor C. Basile (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials
Ms J. Grover (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
The effect of proprotein convertase subtilisin/kexin type 9 inhibition on the plasma proteome: a SPIRE sub-study
Mr J. Kraaijenhof (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins
Associate Professor R. Santos (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Identification of potent small-molecule PCSK9 inhibitors based on quantitative structure-activity relationship, pharmacophore modeling, and molecular docking procedure.
Professor M. Banach (Lodz, PL)
Abstract Slides Video

Access the full session

Session thumbnail
PCSK9 inhibitors and inclisiran

The Event

Event poster

ESC Congress 2023

28 August 2023 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Early initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: a systematic review and meta-analysis
thumbnail
Congress Presentation
Lower rate of ischemic events with PCSK9 inhibition in patients with atherosclerotic cardiovascular disease but without prior ischemic events
thumbnail
Congress Presentation
Strike early-strike strong lipid-lowering strategy with PCSK9i in ACS patients. Real-world evidence from AT-TARGET-IT registry.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources